Protagonist Therapeutics (PTGX) Cut to Sell at Zacks Investment Research
Protagonist Therapeutics (NASDAQ:PTGX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Saturday.
According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “
A number of other research analysts have also recently weighed in on PTGX. ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 18th. Leerink Swann lifted their target price on Protagonist Therapeutics from $13.00 to $21.00 and gave the company an “outperform” rating in a report on Monday, August 6th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $22.00.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Tuesday, November 6th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01). Protagonist Therapeutics had a negative net margin of 70.54% and a negative return on equity of 24.08%. The firm had revenue of $6.12 million during the quarter, compared to analyst estimates of $6.35 million. Research analysts expect that Protagonist Therapeutics will post -1.58 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of PTGX. FMR LLC raised its position in Protagonist Therapeutics by 8.7% in the third quarter. FMR LLC now owns 3,457,402 shares of the company’s stock valued at $35,577,000 after purchasing an additional 276,819 shares during the period. BlackRock Inc. raised its position in Protagonist Therapeutics by 39.0% in the first quarter. BlackRock Inc. now owns 687,160 shares of the company’s stock valued at $5,904,000 after purchasing an additional 192,632 shares during the period. Renaissance Technologies LLC raised its position in Protagonist Therapeutics by 816.3% in the second quarter. Renaissance Technologies LLC now owns 478,300 shares of the company’s stock valued at $3,214,000 after purchasing an additional 426,100 shares during the period. Jennison Associates LLC purchased a new position in Protagonist Therapeutics in the third quarter valued at about $3,598,000. Finally, Millennium Management LLC raised its position in Protagonist Therapeutics by 66.4% in the first quarter. Millennium Management LLC now owns 320,739 shares of the company’s stock valued at $2,755,000 after purchasing an additional 128,009 shares during the period. Hedge funds and other institutional investors own 57.34% of the company’s stock.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.